Literature DB >> 6699475

Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia.

J G Kelton, D Sheridan, H Brain, P J Powers, A G Turpie, C J Carter.   

Abstract

It is important to confirm the diagnosis of heparin-associated thrombocytopenia, because discontinuation of heparin requires the institution of other antithrombotic therapy. Reports describing a heparin-dependent platelet-aggregating factor in the serum of patients with heparin-associated thrombocytopenia suggest the potential for a specific diagnostic test. No study has evaluated the diagnostic usefulness of testing for this factor, and we tested for a heparin-dependent platelet-aggregating factor in sera from (1) 14 patients with heparin-associated thrombocytopenia, (2) 14 nonthrombocytopenic controls given heparin, (3) 16 patients with consumptive thrombocytopenic disorders not associated with heparin, and (4) 13 healthy laboratory personnel. Coded serum samples plus varying concentrations of heparin (final concentration 0.01, 0.1, 1.0, and 5 U/ml) plus platelets from healthy individuals were incubated together, and aggregation was measured. Positive results (greater than 20% aggregation) occurred in (1) five of 14 patients with heparin-associated thrombocytopenia, (2) 0 of 16 consumptive thrombocytopenic controls not given heparin therapy, (3) one of 14 nonthrombocytopenic controls given heparin, and (4) one of 13 healthy controls, giving a sensitivity of 36% and specificities of 100%, 93%, and 92%, respectively. No unique clinical or laboratory feature distinguished those patients with heparin-associated thrombocytopenia with positive aggregation results from those patients with heparin-associated thrombocytopenia with negative results. Fourteen of the 16 patients (86%) with heparin-associated thrombocytopenia had elevated levels of platelet-associated IgG; however, the test was also positive in 67% of the 16 patients with other consumptive (and probably immune) thrombocytopenic disorders not associated with heparin administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6699475

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  14 in total

Review 1.  Perspectives on the long term management of heparin-induced thrombocytopenia.

Authors:  D Brieger
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 2.  Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

Review 3.  Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants.

Authors:  Albrecht Leo; Susanne Winteroll
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 4.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

5.  Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Gonzalo Díaz; Patricia Hidalgo; Isabel Pizarro; Eric Jara; Patricio Rojas; Guillermo Quiroga; Rodrigo Moore-Carrasco
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

6.  White clot syndrome and continuous arteriovenous haemofiltration.

Authors:  M P Shelly; R V Majer; C Perkins; T Pierce; M S Nielsen
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 7.  Heparin-induced thrombocytopenia: molecular pathogenesis.

Authors:  Seon Ho Lee; Chao Yan Liu; Gian PaoloVisentin
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

Authors:  P F Leyvraz; F Bachmann; J Hoek; H R Büller; M Postel; M Samama; M D Vandenbroek
Journal:  BMJ       Date:  1991-09-07

Review 9.  Benefit-risk assessment of treatments for heparin-induced thrombocytopenia.

Authors:  Harry Messmore; Walter Jeske; William Wehrmacher; Jeanine Walenga
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

Authors:  Niyati H Vakil; Abir O Kanaan; Jennifer L Donovan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.